J&J to Accelerate Ebola Vaccine Development
This article is for subscribers only.
Johnson & Johnson said it will fast-track the development of a new combination vaccine regimen against Ebola amid a race to combat the worst outbreak of the deadly disease on record.
The company will collaborate with Denmark-based biotech company Bavarian Nordic and the National Institute of Allergy and Infectious Diseases, it said in a statement today. They will work toward starting a clinical trial in humans in early 2015.